In Silico Ligand-Based Screening of PDB Database for Searching Unique Motifs Against SARS-CoV-2
Biomolecules · 2026
DOI: 10.3390/biom16010163 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2026. Verfasst von Andrey V Machulin und 4 weiteren Autor:innen. Beteiligte Einrichtung: G.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center Pushchino Scientific Center for Biological Research…. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, Databases, Protein, Antiviral Agents. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: government funding.
Abstract (Originalsprache)
SARS-CoV-2, the virus responsible for coronavirus disease COVID-19, is a highly transmissible pathogen that has caused substantial global morbidity and mortality. The ongoing COVID-19 pandemic caused by this virus has had a significant impact on public health and the global economy. One approach to combating COVID-19 is the development of broadly neutralizing antibodies for prevention and treatment. In this work, we performed an in silico ligand-based screening of the PDB database to search for unique anti-SARS-CoV-2 motifs. The collected data were organized and presented in a classified SARS-CoV-2 Ligands Database, categorized based on the number of ligands and structural components of the spike glycoprotein. The database contains 1797 entries related to the structures of the spike glycoprotein (UniProt ID: P0DTC2), including both full-length molecules and their fragments (individual domains and their combinations) with various ligands, such as angiotensin-converting enzyme II and antibodies. The database’s capabilities allow users to explore various datasets according to the research objectives. To search for motifs in the receptor-binding domain (RBD) most frequently involved in antibody binding sites, antibodies were classified into four classes according to their location on the RBD; for each class, special binding motifs are revealed. In the RBD binding sites, specific tyrosine-containing motifs were found. Data obtained may help speed up the creation of new antibody-based therapies, and guide the rational design of next-generation vaccines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- G.K. Skryabin Institute of Biochemistry and Physiology of Microorganisms, Federal Research Center Pushchino Scientific Center for Biological Research, Russian Academy of Sciences, 142290 Pushchino, Russia.
- Moscow Timiryazev Agricultural Academy, Russian State Agrarian University, 127434 Moscow, Russia.
- Institute of Protein Research, Russian Academy of Sciences, 142290 Pushchino, Russia.
- Institute for Biological Instrumentation, Federal Research Center Pushchino Scientific Center for Biological Research, Russian Academy of Sciences, 142290 Pushchino, Russia.
- Gamaleya National Research Center for Epidemiology and Microbiology, 123098 Moscow, Russia.
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, 142290 Pushchino, Russia.
ORCID-Profile: Andrey V Machulin, Sergei Y Grishin, Evgeniya I Deryusheva, Oxana V Galzitskaya
Förderung
- government funding
Zitieren
APA
Machulin, A. V., Badaeva, J. V., Grishin, S. Y., Deryusheva, E. I., & Galzitskaya, O. V. (2026). In Silico Ligand-Based Screening of PDB Database for Searching Unique Motifs Against SARS-CoV-2. Biomolecules. https://doi.org/10.3390/biom16010163
Vancouver
Machulin AV, Badaeva JV, Grishin SY, Deryusheva EI, Galzitskaya OV. In Silico Ligand-Based Screening of PDB Database for Searching Unique Motifs Against SARS-CoV-2. Biomolecules. 2026. doi:10.3390/biom16010163
BibTeX
@article{Machulin2026,
author = {Machulin, Andrey V and Badaeva, Juliya V and Grishin, Sergei Y and Deryusheva, Evgeniya I and Galzitskaya, Oxana V},
title = {In Silico Ligand-Based Screening of PDB Database for Searching Unique Motifs Against SARS-CoV-2},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16010163}
}
EUVIMED